---
title: 'Stereotactic central/core ablative radiation therapy: results of a phase I
  study of a novel strategy to treat bulky tumor'
date: '2024-06-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38854732/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240610182540&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: SCART was safely escalated to 24 GyX 3 fractions, which
  is the maximum Tolerated Dose (MTD) for SCART. This regimen will be used in future
  phase II ...'
disable_comments: true
---
CONCLUSION: SCART was safely escalated to 24 GyX 3 fractions, which is the maximum Tolerated Dose (MTD) for SCART. This regimen will be used in future phase II ...